Anti-RANTES抗体(Biotin) (ab83135)

概述

  • 产品名称Anti-RANTES抗体(Biotin)
    参阅全部 RANTES 一抗
  • 描述
    兔多克隆抗体to RANTES (Biotin)
  • 偶联物Biotin
  • 经测试应用适用于: ELISA, Sandwich ELISA, WBmore details
  • 种属反应性
    与反应: Mouse
  • 免疫原

    Highly pure (>98%) recombinant mouse RANTES

性能

应用

Our Abpromise guarantee covers the use of ab83135 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA
Sandwich ELISA
WB
  • 应用说明ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant murine RANTES.
    sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant murine RANTES.
    Can be paired for ELISA with Rabbit polyclonal to RANTES (ab9915)
    WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant murine RANTES is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 10 kDa.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • 靶标

    • 功能Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils.
    • 组织特异性T-cell and macrophage specific.
    • 序列相似性Belongs to the intercrine beta (chemokine CC) family.
    • 翻译后修饰N-terminal processed form RANTES(3-68) is produced by proteolytic cleavage, probably by DPP4, after secretion from peripheral blood leukocytes and cultured sarcoma cells.
      The identity of the O-linked saccharides at Ser-27 and Ser-28 are not reported in PubMed:1380064. They are assigned by similarity.
    • 细胞定位Secreted.
    • Information by UniProt
    • 数据库链接
    • 别名
      • Beta chemokine RANTES antibody
      • Beta chemokine RANTES precursor antibody
      • C C motif chemokine 5 antibody
      • CCL 5 antibody
      • CCL5 antibody
      • CCL5_HUMAN antibody
      • Chemokine (C C motif) ligand 5 antibody
      • Chemokine CC Motif Ligand 5 antibody
      • D17S136E antibody
      • EoCP antibody
      • Eosinophil chemotactic cytokine antibody
      • MGC17164 antibody
      • RANTES(4-68) antibody
      • Regulated upon activation normally T expressed and presumably secreted antibody
      • SCYA 5 antibody
      • SCYA5 antibody
      • SIS delta antibody
      • SIS-delta antibody
      • SISd antibody
      • Small inducible cytokine A5 (RANTES) antibody
      • Small inducible cytokine A5 antibody
      • Small inducible cytokine subfamily A (Cys Cys) member 5 antibody
      • Small-inducible cytokine A5 antibody
      • T cell specific protein p288 antibody
      • T cell specific RANTES protein antibody
      • T cell-specific protein P228 antibody
      • T-cell-specific protein RANTES antibody
      • TCP 228 antibody
      • TCP228 antibody
      see all

    Anti-RANTES antibody (Biotin) (ab83135)参考文献

    ab83135 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for contacting us.

    The protein sequence compatibility between human and mouse with bovine is about 80% which is very close for antibody cross reactivity. We unfortunately haven't tested any of the antibody with bovine CCL5 so I am so...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"